Kingworld Medicines Group Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kingworld Medicines Group.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Apr 23

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kingworld Medicines Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1110 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	1,079	38	N/A	N/A	N/A
9/30/2023	1,085	37	N/A	N/A	N/A
6/30/2023	1,091	36	34	177	N/A
3/31/2023	1,024	29	64	182	N/A
12/31/2022	958	23	93	187	N/A
9/30/2022	905	29	66	159	N/A
6/30/2022	852	35	40	131	N/A
3/31/2022	850	33	31	106	N/A
12/31/2021	847	30	23	81	N/A
9/30/2021	858	26	76	111	N/A
6/30/2021	868	21	129	141	N/A
3/31/2021	807	17	121	132	N/A
12/31/2020	745	12	114	124	N/A
9/30/2020	749	16	90	99	N/A
6/30/2020	752	20	66	74	N/A
3/31/2020	865	32	95	103	N/A
12/31/2019	978	43	124	133	N/A
9/30/2019	1,010	45	79	88	N/A
6/30/2019	1,041	46	34	44	N/A
3/31/2019	1,060	44	42	53	N/A
12/31/2018	1,079	41	51	62	N/A
9/30/2018	1,079	49	60	85	N/A
6/30/2018	1,079	56	70	108	N/A
3/31/2018	1,055	54	51	90	N/A
12/31/2017	1,031	51	32	72	N/A
9/30/2017	1,088	50	N/A	58	N/A
6/30/2017	1,145	49	N/A	43	N/A
3/31/2017	1,099	48	N/A	20	N/A
12/31/2016	1,054	47	N/A	-4	N/A
9/30/2016	909	41	N/A	20	N/A
6/30/2016	764	35	N/A	44	N/A
3/31/2016	739	34	N/A	74	N/A
12/31/2015	714	32	N/A	103	N/A
9/30/2015	711	34	N/A	56	N/A
6/30/2015	708	36	N/A	10	N/A
3/31/2015	684	37	N/A	2	N/A
12/31/2014	660	38	N/A	-5	N/A
9/30/2014	640	43	N/A	-21	N/A
6/30/2014	619	48	N/A	-38	N/A
3/31/2014	587	48	N/A	-44	N/A
12/31/2013	555	47	N/A	-50	N/A
9/30/2013	571	47	N/A	-11	N/A
6/30/2013	587	48	N/A	28	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1110's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 1110's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1110's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1110's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1110's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1110's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Kingworld Medicines Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Recent updates

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Kingworld Medicines Group Limited, Annual General Meeting, May 29, 2024

Full year 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.037 in FY 2022)

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group Limited to Report Fiscal Year 2023 Final Results on Mar 26, 2024

Now 29% overvalued

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.064 (vs CN¥0.04 in 1H 2022)

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

Kingworld Medicines Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 3.0% yield

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Full year 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.05 in FY 2021)

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Investor sentiment improved over the past week

Insufficient new directors

Now 22% undervalued after recent price drop

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Now 24% undervalued

First half 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.032 in 1H 2021)

Kingworld Medicines Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Co-Founder recently bought HK$297k worth of stock

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group Limited Announces Final Cash Dividend for the Financial Year Ended 31 December 2021, Payable on 30 June 2022

Upcoming dividend of HK$0.024 per share

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Less than half of directors are independent

Co-Founder recently bought HK$280k worth of stock

Kingworld Medicines Group Limited Announces Final Dividend for the Year Ended 31 December 2021, Payable on 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.05 (vs CN¥0.019 in FY 2020)

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

Kingworld Medicines Group Limited, Annual General Meeting, May 27, 2022

First half 2021 earnings released: EPS CN¥0.032 (vs CN¥0.016 in 1H 2020)

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Declares Final Dividend for the Year Ended December 31, 2020

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.019 (vs CN¥0.07 in FY 2019)

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2020

Kingworld Medicines Group Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

New 90-day low: HK$0.67

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

New 90-day low: HK$0.73

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Kingworld Medicines Group Limited Enters Distribution Agreement with Shenzhen Ausa Pharmaceutical Co., Ltd

Executive Director recently sold HK$1.3m worth of stock

New 90-day high: HK$0.80

First half earnings released

New 90-day low - HK$0.71

First half earnings released

Kingworld Medicines Group Limited to Report First Half, 2020 Results on Aug 26, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies